HBP:CC - Helix BioPharma Corp. Announces Upcoming Poster Presentation at the 20th European Molecular Imaging Meeting in Bilbao, Spain
(TheNewswire)
March 11, 2025 – TheNewswire - Toronto, Ontario – Helix BioPharma Corp. (TSX: “HBP” , OTC PINK: “HBPCD” , FRANKFURT: “HBP0” ) ( “Helix” or the “Company” ), a clinical-stage oncology company shaping a near futurewhere today’s hard-to-treat cancers are vincible, is pleased toannounce an upcoming poster presentation highlighting the effects ofTumour Defence Breaker™, L-DOS47, in CEACAM6-expressing head andneck cancer cells and colon adenocarcinoma cells in tumor-bearing miceat the 20 th European Molecular Imaging Meeting ( “EMIM 2025” )taking place 11–14 March in Bilbao, Spain.
The study demonstrated that L-DOS47 effectivelyneutralizes the acidic tumor microenvironment (TME) in newCEACAM6-expressing solid tumors, a critical factor in tumorprogression and immune evasion. In head and neck cancer and colonadenocarcinoma models, treatment with L-DOS47 raised tumor pH levelswithin 24 hours with a transient but measurable effect lasting up to48 hours, effectively neutralizing acidity that fuels tumor growth.MRI scans and tissue analysis also revealed signs of tumor necrosis,underscoring L-DOS47’s impact on tumor viability. Importantly, thestudy confirmed that L-DOS47 precisely targets CEACAM6-expressingtumors while being safely cleared from the body. These results add tothe growing evidence that L-DOS47 is a powerful Tumour DefenceBreaker™, shifting the tumor microenvironment to make prevalent,hard-to-treat cancers more vulnerable to treatment. The abstract andposter are publicly available on EMIM 2025’s Event Class via thefollowing link: https://www.eventclass.it/emim2025/scientific/online-program/poster-session?s=PO+01
Poster details:
Title: Paradigm Change in Oncoimmunology: Tumor antigen specificnormalization of the extracellular pH in the tumor microenvironment ofsolid tumors by L-DOS47.
Session: Poster Session I
Presentation date: Wednesday, 12 March 2025
Abstract Number: ONCO-011
Presenters: Dimitri Stowbur, PhD, Postdoctoral Reasearch Fellow in CancerImmunotherapy and Modulation of the Tumor Microenvironment, and CsabaToemboely, PhD, Senior Researcher in Imaging probe development andcancer immunotherapy at the University of Tuebingen.
About the European Molecular Imaging Meeting (EMIM)Annual Meeting
The European Molecular Imaging Meeting (EMIM) is aleading international conference dedicated to advancing molecularimaging and its applications in biomedical research. Organized by theEuropean Society for Molecular Imaging (ESMI), the 20 th EMIM bringstogether over 1,100 scientists, clinicians, and industry experts toexplore the latest breakthroughs in imaging technologies, biomarkers,and translational research. The 2025 meeting will take place inBilbao, Spain, from March 11–14, providing a platform forcutting- edge presentations, collaborativediscussions, and emerging innovations that drive the future ofmolecular imaging. For more information, visit: https://e-smi.eu/ .
About Helix BioPharma
Helix BioPharma Corp. is an oncology company shaping anear future where today’s hard-to-treat cancers are made vincible bynovel therapies that rise to the challenge. The Company innovates fromstrength to tackle cancer’s biggest, most urgent challenges with adiverse pipeline of drug candidates with great potential and a headstart, honed into first- and best-in-class oncology medicines. Itspipeline is spearheaded by a clinical-stage proprietary technologyplatform of bio-conjugates that score with precision against prevalentCEACAM6-expressing solid tumors. Its lead candidate, Tumour DefenceBreaker TM L-DOS47, is a clinical-stage antibody-enzyme conjugate (AEC)that neutralizes the microenvironment of common, hard-to-treat solidtumors, taking the brakes off anti-cancer immunity and delivering agame-changing assist to today’s front-running anti-cancer therapies.L-DOS47 has completed Phase Ib studies in non-small cell lung cancer(NSCLC), with novel strategically designed bi-specific ADCs targetingCEACAM6 in discovery.
Helix is listed on the TSX under the symbol “HBP”,on OTC PINK under the symbol “HBPCD” and on FWB under the symbol“HBP0”. For more information, please visit: https://www.helixbiopharma.com/
For more information, pleasecontact:
Helix BioPharma Corp.
Bay Adelaide Centre - North Tower
40 Temperance Street, Suite 2
Toronto, ON M5H 0B4
Tel: 604-428-7050
Jacek Antas, Director
Forward-Looking Statements and Risksand Uncertainties
This news release contains certainstatements regarding Helix BioPharma Corp. that constituteforward-looking statements and information (collectively, “forwardlooking statements”) as defined by Canadian securities laws.Forward-looking statements include and are not limited to financialprojections and expectations regarding Helix’s future business andoperations, particularly related to the Company’s CEACAM6 platform,DOS47 and new asset transactions that Helix intends to close. Thesestatements use terms like “estimates,” “expects,” “will,”and similar language indicating future events, or the negative thereofor any other comparable terminology referring to future events orresults.
However, forward-looking statementsare subject to risks and uncertainties beyond Helix’s control,which may lead to actual results differing materially from thoseanticipated. These risks and uncertainties include, but are notlimited to, risks relating to Helix’s financial condition, including(a) lack of significant revenues to date and reliance on equity andother financing; (b) business, including its stage of development,government regulation, development success of and market acceptancefor its products, rapid technological change and dependence on keypersonnel; (c) intellectual property including the ability of Helix toprotect its intellectual property and dependence on its strategicpartners; and (d) capital structure, including its lack of dividendson its common shares, volatility of the market price of its commonshares and public company costs. Forward-looking statements reflectthe management’s current beliefs and are based on informationavailable to the management on the date of this news release, and theCompany does not assume the obligation to update any forward-lookingstatement should those beliefs change, except as required bylaw. Further information regarding these risks and uncertainties canbe found in Helix’s periodic reports and information forms on theCompany’s SEDAR+ profile at www.sedarplus.ca .
_________________
Copyright (c) 2025 TheNewswire - All rights reserved.